PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine‐induced hepatic steatosis via both receptor‐dependent and receptor‐independent pathways

Schizophrenia, affecting approximately 1% of the global population, is often treated with olanzapine. Despite its efficacy, olanzapine's prolonged use has been associated with an increased risk of cardiovascular diseases and nonalcoholic fatty liver disease (NAFLD); however, the underlying mech...

Ausführliche Beschreibung